Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Coronavirus, Other Infectious Diseases In Focus

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering the business week ended 17 July.

This week, there are calls for a renewed focus on and investment in infectious diseases in general, as coronavirus vaccine and drug developments continue to attract substantial attention.

Stories mentioned in this episode:

(Also see "Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses" - Scrip, 14 Jul, 2020.)

(Also see "Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism" - Scrip, 10 Jul, 2020.)

(Also see "Novartis Unveils Zero Profit COVID-19 Drugs Portfolio" - Scrip, 16 Jul, 2020.)

(Also see "Big Pharma’s $1Bn Antibiotic Development Fund Offers ‘Breathing Room’ For Reimbursement Fix" - Scrip, 9 Jul, 2020.)

(Also see "Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base" - Scrip, 15 Jul, 2020.)







Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts